INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,481,000 | -43.1% | 59,970 | -4.6% | 0.00% | -50.0% |
| Q3 2020 | $2,605,000 | -19.0% | 62,843 | -6.4% | 0.00% | -33.3% |
| Q2 2020 | $3,215,000 | -24.1% | 67,111 | -0.2% | 0.00% | -40.0% |
| Q1 2020 | $4,235,000 | -54.6% | 67,258 | -10.6% | 0.01% | -44.4% |
| Q4 2019 | $9,321,000 | +74.3% | 75,216 | -6.7% | 0.01% | +50.0% |
| Q3 2019 | $5,349,000 | -16.1% | 80,602 | +0.6% | 0.01% | -14.3% |
| Q2 2019 | $6,374,000 | -21.1% | 80,109 | +5.4% | 0.01% | +40.0% |
| Q1 2019 | $8,078,000 | +111.1% | 75,974 | +100.1% | 0.01% | 0.0% |
| Q4 2018 | $3,826,000 | -21.3% | 37,964 | -1.3% | 0.01% | -16.7% |
| Q3 2018 | $4,862,000 | +30.0% | 38,475 | -13.7% | 0.01% | +20.0% |
| Q2 2018 | $3,741,000 | +52.9% | 44,587 | +12.2% | 0.01% | +66.7% |
| Q1 2018 | $2,446,000 | +5.1% | 39,752 | -0.3% | 0.00% | 0.0% |
| Q4 2017 | $2,328,000 | +198.5% | 39,852 | +196.6% | 0.00% | +200.0% |
| Q3 2017 | $780,000 | – | 13,436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |